Central AsianResearch Index

NATIONWIDE IMPLEMENTATION OF WHO-RECOMMENDED RAPID MOLECULAR DIAGNOSTICS FOR TUBERCULOSIS IN TAJIKISTAN: EPIDEMIOLOGICAL IMPACT ON RIFAMPICIN RESISTANCE TRENDS (2019–2024)

Purpose of the study. This study evaluated the effectiveness of tuberculosis (TB) diagnostics in Tajikistan in accordance with World Health Organization (WHO) recommendations following nationwide introduction of rapid molecular tests Xpert® MTB/RIF Ultra and Xpert® MTB/XDR. Materials and methods. A decentralized TB diagnostic network comprising 78 GeneXpert instruments across 69 sites was analyzed. Pediatric TB diagnosis included testing of stool samples using Xpert MTB/RIF Ultra. Turnaround times for positive and negative results were recorded, and GeneXpert data from 2019 to 2024 were analyzed to assess trends in rifampicin-resistant TB. Results. Xpert MTB/RIF Ultra detects Mycobacterium tuberculosis DNA and rifampicin resistance within approximately two hours, while Xpert MTB/XDR identifies resistance to INH, FLQ, ETH and SLID. Turnaround times were 77 minutes for positive and 65 minutes for negative results with Xpert MTB/RIF Ultra, and 90 minutes with Xpert MTB/XDR. The proportion of rifampicin-resistant TB among MTB-positive cases declined from 18.5% in 2019 to 11.0% in 2024. Conclusion. Nationwide adoption of WHO-recommended rapid molecular diagnostics has strengthened TB detection and drug-resistance surveillance in Tajikistan and has contributed to a sustained reduction in rifampicin-resistant TB over the six-year period.

Сведения

Опубликовано
2026 · Т. 10, № 2
Источник
cyberleninka.ru
Язык
Английский
ISSN
3107-2356
Издатель
Высшая аттестационная комиссия при Президенте Республики Таджикистан